目的 探討腦心清膠囊聯(lián)合美托洛爾治療穩(wěn)定型心絞痛的臨床療效。方法 選擇2021年6月—2023年6月在南通市海門區(qū)人民醫(yī)院治療的110例穩(wěn)定型心絞痛患者為研究對象，隨機(jī)分為對照組和治療組，每組各55例。對照組口服琥珀酸美托洛爾緩釋片，23.75 mg/d。治療組在對照組基礎(chǔ)上口服腦心清膠囊，0.9 g/次，3次/d。兩組患者均持續(xù)治療2個(gè)月。觀察兩組臨床療效，比較治療前后兩組臨床癥狀改善情況、心功能、血液流變學(xué)指標(biāo)、血脂指標(biāo)。結(jié)果 治療后，治療組總有效率為94.55%，相較對照組（72.73%）明顯上升（P＜0.05）。治療后，兩組心絞痛持續(xù)時(shí)間、發(fā)作次數(shù)和心肌缺血總負(fù)荷均顯著降低（P＜0.05），且治療組明顯低于對照組（P＜0.05）。治療后，兩組左心室舒張末期內(nèi)徑（LVEDD）明顯降低，而左室射血分?jǐn)?shù)（LVEF）、每搏量（SV）和6 min步行距離均升高（P＜0.05），且治療組患者這些心功能指標(biāo)明顯好于對照組（P＜0.05）。治療后，兩組血漿黏度、全血高切黏度、全血低切黏度及纖維蛋白原水平明顯降低（P＜0.05），且治療后治療組比對照組降低更顯著（P＜0.05）。治療后，兩組三酰甘油（TG）、總膽固醇（TC）和低密度脂蛋白膽固醇（LDL-C）水平均顯著降低，而高密度脂蛋白膽固醇（HDL-C）水平顯著升高（P＜0.05），且治療組明顯好于對照組（P＜0.05）。結(jié)論 腦心清膠囊聯(lián)合美托洛爾治療穩(wěn)定型心絞痛療效顯著，可有效改善臨床癥狀、增強(qiáng)患者心功能，且安全可靠。

Objective To investigate the clinical efficacy of Naoxinqing Capsules combined with metoprolol in treatment of effort angina pectoris. Methods Patients (110 cases) with effort angina pectoris in Nantong Haimen People’s Hospital from June 2021 to June 2023 were randomly divided into control and treatment group, and each group had 55 cases. Patients in the control group were po administered with Metoprolol Succinate Sustained-release Tablets, 23.75 mg/d. Patients in the treatment group were po administered with Naoxinqing Capsules on the basis of the control group, 0.9 g/time, three time daily. Patients in two groups were treated for 2 month. After treatment, the clinical evaluations were evaluated, improvement of clinical symptoms, cardiac function status, blood rheology indexes, and blood lipid indexes in two groups before and after treatment were compared. Results After treatment, the total effective rate in the treatment group was 94.55%, significantly higher than 72.73% in the control group (P < 0.05). After treatment, the duration and frequency of angina pectoris and total myocardial ischemic load in 2 groups were significantly decreased (P < 0.05). And the duration and frequency of angina pectoris and total myocardial ischemic load were lower than those in control group (P < 0.05). After treatment, the LVEDD was significantly decreased in both groups (P < 0.05), while LVEF, SV, and 6 min walking distance was significantly increased in both groups (P < 0.05). And LVEDD, LVEF, SV, and 6 min walking distance in treatment group were better than those in control group (P < 0.05). After treatment, the plasma viscosity, whole blood high shear viscosity, whole blood low shear viscosity, and fibrinogen in the treatment group were lower than those in the control group (P < 0.05). After treatment, the reduction was more significant in the treatment group than in the control group (P < 0.05). After treatment, the levels of triglyceride (TG), total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) in both groups were significantly decreased, but the levels of high density lipoprotein cholesterol (HDL-C) were significantly increased (P < 0.05), and the treatment group was significantly better than the control group (P < 0.05). Conclusion Naoxinqing Capsules combined with metoprolol has good efficacy in treatment of effort angina pectoris, can effectively improve patients’ clinical symptoms and enhance their cardiac function with good efficacy and safety.

R972

江蘇省衛(wèi)生健康委科研課題(ZD2020038)